• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Saxonov Serge

    3/25/26 5:15:13 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Saxonov Serge

    (Last)(First)(Middle)
    10X GENOMICS, INC.
    6230 STONERIDGE MALL ROAD

    (Street)
    PLEASANTON CALIFORNIA 94588

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    10x Genomics, Inc. [ TXG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/23/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class A Common Stock03/23/2026S(1)10,000D$19.1297(2)1,177,273(3)D
    Class A Common Stock03/24/2026S(1)5,000D$19.5223(4)1,172,273D
    Class A Common Stock27ISee footnote(5)
    Class A Common Stock213,250ISee footnote(6)
    Class A Common Stock71,644(3)ISee footnote(7)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Class B Common Stock(8) (8) (8)Class A Common Stock1,100,9271,100,927(9)D
    Class B Common Stock(8) (8) (8)Class A Common Stock180,938180,938(9)ISee footnote(10)
    Class B Common Stock(8) (8) (8)Class A Common Stock1,750,0001,750,000ISee footnote(11)
    Explanation of Responses:
    1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
    2. This transaction was executed in multiple trades at prices ranging from $18.78 to $19.41, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
    3. Reflects the transfer by the Reporting Person of 13,644 shares of Class A Common Stock to the Y/S Pot Trust on March 3, 2026.
    4. This transaction was executed in multiple trades at prices ranging from $19.49 to $19.59, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
    5. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
    6. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
    7. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
    8. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.
    9. Reflects the transfer by the Reporting Person of 91,113 shares of Class B Common Stock to the Sirius Trust on March 3, 2026.
    10. The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
    11. 250,000 shares are held by each of Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, of which the Reporting Person is the sole trustee.
    /s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov03/25/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $TXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    3/31/2026Mkt Perform → Outperform
    William Blair
    12/11/2025Buy → Neutral
    Citigroup
    12/2/2025$20.00Overweight → Equal-Weight
    Morgan Stanley
    9/11/2025$15.00Neutral
    Piper Sandler
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saxonov Serge sold $709,057 worth of shares (28,893 units at $24.54) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,138,380 units (SEC Form 4) to satisfy withholding tax

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    5/27/26 5:57:37 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Hindson Benjamin J. sold $283,399 worth of shares (11,595 units at $24.44), decreasing direct ownership by 2% to 502,000 units (SEC Form 4) to satisfy tax liability

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    5/27/26 5:56:46 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Taich Adam sold $369,018 worth of shares (15,098 units at $24.44), decreasing direct ownership by 4% to 379,898 units (SEC Form 4) to cover taxes

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    5/27/26 5:55:41 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    SEC Filings

    View All

    10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - 10x Genomics, Inc. (0001770787) (Filer)

    5/7/26 4:03:31 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by 10x Genomics Inc.

    DEFA14A - 10x Genomics, Inc. (0001770787) (Filer)

    4/24/26 4:08:29 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by 10x Genomics Inc.

    DEF 14A - 10x Genomics, Inc. (0001770787) (Filer)

    4/24/26 4:06:36 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    10x Genomics upgraded by William Blair

    William Blair upgraded 10x Genomics from Mkt Perform to Outperform

    3/31/26 8:05:20 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Citigroup

    Citigroup downgraded 10x Genomics from Buy to Neutral

    12/11/25 8:24:15 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded 10x Genomics from Overweight to Equal-Weight and set a new price target of $20.00

    12/2/25 8:22:39 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    10x Genomics Reports First Quarter 2026 Financial Results

    PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood.

    5/7/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference

    PLEASANTON, Calif., April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10

    4/29/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, April 29, 2026 /CNW/ -- Equity-Insider.com News Commentary – Here's the quiet shift in medtech right now: the global medical imaging market is on track to grow from $41.64 billion in 2024 to $67.87 billion by 2034[1], and capital has stopped chasing every shiny promise. That pressure got real in April, when the FDA advanced its real-world evidence framework for medical devices[2], lining regulators and payers up around documented performance instead of trial-stage pitches. Five names keep showing up in that conversation: VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Senseonics (NASDAQ:SENS), TransMedics Group (NASDAQ:TMDX),

    4/29/26 9:00:00 AM ET
    $SENS
    $TMDX
    $TXG
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Laboratory Analytical Instruments

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/25 5:22:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    View All

    10x Genomics Announces Senior Leadership Changes

    PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

    8/8/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care

    ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

    Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

    1/10/22 8:00:00 AM ET
    $RARE
    $TXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/8/24 2:46:37 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/5/24 6:07:26 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

    SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    10/4/24 2:14:32 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Financials

    Live finance-specific insights

    View All

    10x Genomics Reports First Quarter 2026 Financial Results

    PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood.

    5/7/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026

    PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's

    4/15/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

    PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, rep

    2/12/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials